These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 8989921)
1. Comparative study on expression of plasminogen activator inhibitor 1 and its mRNA in endometrial cancers and normal endometria. Fujimoto J; Hori M; Ichigo S; Hirose R; Sakaguchi H; Tamaya T Tumour Biol; 1997; 18(1):13-21. PubMed ID: 8989921 [TBL] [Abstract][Full Text] [Related]
2. Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa. Fujimoto J; Hori M; Ichigo S; Tamaya T J Steroid Biochem Mol Biol; 1996 Sep; 59(1):1-8. PubMed ID: 9009232 [TBL] [Abstract][Full Text] [Related]
3. Expression of basic fibroblast growth factor and its mRNA in uterine endometrial cancers. Fujimoto J; Hori M; Ichigo S; Tamaya T Invasion Metastasis; 1995; 15(5-6):203-10. PubMed ID: 8765195 [TBL] [Abstract][Full Text] [Related]
4. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Foca C; Moses EK; Quinn MA; Rice GE Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652 [TBL] [Abstract][Full Text] [Related]
5. Expressions of the fibroblast growth factor family (FGF-1, -2 and -4) mRNA in endometrial cancers. Fujimoto J; Hori M; Ichigo S; Tamaya T Tumour Biol; 1996; 17(4):226-33. PubMed ID: 8685603 [TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer. Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981 [TBL] [Abstract][Full Text] [Related]
8. Expressions of vascular endothelial growth factor (VEGF) and its mRNA in uterine endometrial cancers. Fujimoto J; Ichigo S; Hirose R; Sakaguchi H; Tamaya T Cancer Lett; 1998 Dec; 134(1):15-22. PubMed ID: 10381125 [TBL] [Abstract][Full Text] [Related]
9. Expression of platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA in uterine endometrial cancers. Fujimoto J; Ichigo S; Sakaguchi H; Hirose R; Tamaya T Cancer Lett; 1998 Aug; 130(1-2):115-20. PubMed ID: 9751263 [TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity. Gilabert-Estellés J; Ramón LA; Braza-Boïls A; Gilabert J; Chirivella M; España F; Estellés A Thromb Res; 2012 Aug; 130(2):242-7. PubMed ID: 22055623 [TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569 [TBL] [Abstract][Full Text] [Related]
12. Presence of urokinase plasminogen activator and plasminogen activator inhibitor-1 messenger ribonucleic acids in rat endometrium during decidualization in vivo. Wang S; Kennedy TG; Zhang X Biol Reprod; 1996 Sep; 55(3):493-7. PubMed ID: 8862764 [TBL] [Abstract][Full Text] [Related]
13. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Orejuela FJ; Ramondetta LM; Smith J; Brown J; Lemos LB; Li Y; Hollier LM Gynecol Oncol; 2005 May; 97(2):483-8. PubMed ID: 15863148 [TBL] [Abstract][Full Text] [Related]
14. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer. Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356 [TBL] [Abstract][Full Text] [Related]
15. Sex steroids regulate the expression of plasminogen activator inhibitor-1 and its mRNA in fibroblasts derived from uterine endometrium. Fujimoto J; Hori M; Ichigo S; Tamaya T Ann Clin Biochem; 1996 Nov; 33 ( Pt 6)():545-50. PubMed ID: 8937587 [TBL] [Abstract][Full Text] [Related]
16. Progesterone regulation of plasminogen activator inhibitor 1 (PAI-1) antigen and mRNA levels in human endometrial stromal cells. Casslén B; Urano S; Ny T Thromb Res; 1992 Apr; 66(1):75-87. PubMed ID: 1384159 [TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas. Osmak M; Babić D; Abramić M; Milicić D; Vrhovec I; Skrk J Neoplasma; 2001; 48(6):462-7. PubMed ID: 11949838 [TBL] [Abstract][Full Text] [Related]
18. Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Krzeslak A; Wojcik-Krowiranda K; Forma E; Jozwiak P; Romanowicz H; Bienkiewicz A; Brys M Pathol Oncol Res; 2012 Jul; 18(3):721-8. PubMed ID: 22270867 [TBL] [Abstract][Full Text] [Related]
19. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533 [TBL] [Abstract][Full Text] [Related]
20. In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue. Bruse C; Radu D; Bergqvist A Mol Hum Reprod; 2004 Mar; 10(3):159-66. PubMed ID: 14981142 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]